MUC1 Antibody-Based Therapeutics: The Promise of Cancer Immunotherapy

References

• Linden S , SuttonP , KarlssonN , KorolikV , McguckinM. Mucins in the mucosal barrier to infection. Mucosal Immunol.1(3), 183–197 (2008).
   PubMed Web of Science ®Google Scholar
• Ostedgaard LS , MoningerTO , McmenimenJDet al. Gel-forming mucins form distinct morphologic structures in airways. Proc. Natl Acad. Sci. USA114(26), 6842–6847 (2017).
   PubMed Web of Science ®Google Scholar
• Rachagani S , TorresMP , MoniauxN , BatraSK. Current status of mucins in the diagnosis and therapy of cancer. Biofactors35(6), 509–527 (2009).
   PubMed Web of Science ®Google Scholar
• Horm TM , SchroederJA. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh. Migr.7(2), 187–198 (2013).
   PubMed Web of Science ®Google Scholar
• Dhar P , McauleyJ. The role of the cell surface mucin MUC1 as a barrier to infection and regulator of inflammation. Front. Cell. Infect. Microbiol.9, 117 (2019).
   PubMed Web of Science ®Google Scholar
• Parry S , SilvermanHS , McdermottK , WillisA , HollingsworthMA , HarrisA. Identification of MUC1 proteolytic cleavage sites in vivo. Biochem. Biophys. Res. Commun.283(3), 715–720 (2001).
   PubMed Web of Science ®Google Scholar
• Bennett EP , MandelU , ClausenH , GerkenTA , FritzTA , TabakLA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology22(6), 736–756 (2012).
   PubMed Web of Science ®Google Scholar
• Movahedin M , BrooksTM , SupekarNT , GokanapudiN , BoonsG-J , BrooksCL. Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen. Glycobiology27(7), 677–687 (2017).
   PubMed Web of Science ®Google Scholar
• Piyush T , RhodesJM , YuL-G. MUC1 O-glycosylation contributes to anoikis resistance in epithelial cancer cells. Cell Death Discov.3, 17044 (2017).
   PubMed Web of Science ®Google Scholar
• Lan MS , BatraSK , QiWN , MetzgarRS , HollingsworthMA. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem.265(25), 15294–15299 (1990).
   PubMed Web of Science ®Google Scholar
• Parry S , HanischFG , LeirS-Het al. N-Glycosylation of the MUC1 mucin in epithelial cells and secretions. Glycobiology16(7), 623–634 (2006).
   PubMed Web of Science ®Google Scholar
• Tian E , TenHagen KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj. J.26(3), 325–334 (2009).
   PubMed Web of Science ®Google Scholar
• Ju T , WangY , AryalRPet al. T n and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteom. Clin. Appl.7(9–10), 618–631 (2013).
   PubMed Web of Science ®Google Scholar
• Clausen H , BennettEP. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. Glycobiology6(6), 635–646 (1996).
   PubMed Web of Science ®Google Scholar
• Breloy I , HanischFG. Functional Roles of O-Glycosylation. Molecules23(12), 3063 (2018).
   PubMed Web of Science ®Google Scholar
• Brockhausen I . Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep.7(6), 599–604 (2006).
   PubMed Web of Science ®Google Scholar
• Hanson RL , HollingsworthMA. Functional consequences of differential O-glycosylation of MUC1, MUC4, and MUC16 (downstream effects on signaling). Biomolecules6(3), 34 (2016).
   PubMed Web of Science ®Google Scholar
• Chandrasekaran E , XueJ , XiaJet al. Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II. J. Proteome Res.11(4), 2609–2618 (2012).
   PubMed Web of Science ®Google Scholar
• Saeland E , BeloAI , MongeraS , Van DieI , MeijerGA , Van KooykY. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int. J. Cancer131(1), 117–128 (2012).
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J , BurchellJM , GrahamR , BeatsonR. Latest developments in MUC1 immunotherapy. Biochem. Soc. Trans.46(3), 659–668 (2018).
   PubMedGoogle Scholar
• Burchell J , GendlerS , Taylor-PapadimitriouJet al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res.47(20), 5476–5482 (1987).
   PubMed Web of Science ®Google Scholar
• Posey AD Jr , SchwabRD , BoesteanuACet al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity44(6), 1444–1454 (2016).
   PubMed Web of Science ®Google Scholar
• Weiner LM , MurrayJC , ShuptrineCW. Antibody-based immunotherapy of cancer. Cell148(6), 1081–1084 (2012).
   PubMed Web of Science ®Google Scholar
• Pourjafar M , SamadiP , KhoshinaniHM , SaidijamM. Are mimotope vaccines a good alternative to monoclonal antibodies?Immunotherapy11(9), 795–800 (2019).
   PubMed Web of Science ®Google Scholar
• Scott AM , AllisonJP , WolchokJD. Monoclonal antibodies in cancer therapy. Cancer Immun.12, 14 (2012).
   PubMedGoogle Scholar
• Sameri S , SaidijamM , BahreiniF , NajafiR. Cancer chemopreventive activities of silibinin on colorectal cancer through regulation of E-cadherin/β-catenin pathway. Nutr. Cancer1–11 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Redman J , HillE , AldeghaitherD , WeinerL. Mechanisms of action of therapeutic antibodies for cancer. Mol. Immunol.67(2), 28–45 (2015).
   PubMed Web of Science ®Google Scholar
• Shuptrine CW , SuranaR , WeinerLM. Monoclonal antibodies for the treatment of cancer. Semin. Cancer Biol.22(1), 3–13 (2012).
   PubMed Web of Science ®Google Scholar
• Xu H , GanL , HanYet al. Site-specific labeling of an anti-MUC1 antibody: probing the effects of conjugation and linker chemistry on the internalization process. RSC Adv.9(4), 1909–1917 (2019).
   PubMed Web of Science ®Google Scholar
• Xing P-X , PrenzoskaJ , QuelchK , MckenzieIF. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res.52(8), 2310–2317 (1992).
   PubMed Web of Science ®Google Scholar
• Rivalland G , LovelandB , MitchellP. Update on Mucin-1 immunotherapy in cancer: a clinical perspective. Expert Opin. Biol. Ther.15(12), 1773–1787 (2015).
   PubMed Web of Science ®Google Scholar
• Murawa P , KobylarekR , GraczA , MalickiJ , KierzkowskiJ. Intraperitoneal administration of radiolabelled monoclonal antibody pemtumomab (Yttrium-90-HMFG1) in gastric cancer. Rep. Pract. Oncol. Radiother.8(2), 49–56 (2003).
   Google Scholar
• Xing PX , TjandraJ , StackerSet al. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol. Cell Biol.67(3), 183–195 (1989).
   PubMedGoogle Scholar
• Pericleous L , RichardsJ , EpenetosA , Courtenay-LuckN , DeonarainM. Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1. Br. J. Cancer93(11), 1257 (2005).
   PubMed Web of Science ®Google Scholar
• Pegram MD , BorgesVF , IbrahimNet al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res.11(5), R73 (2009).
   PubMed Web of Science ®Google Scholar
• Ibrahim NK , YarizKO , BondarenkoIet al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor–positive locally advanced or metastatic breast cancer. Clin. Cancer. Res.17(21), 6822–6830 (2011).
   PubMed Web of Science ®Google Scholar
• Corraliza-Gorjón I , Somovilla-CrespoB , SantamariaS , Garcia-SanzJA , KremerL. New strategies using antibody combinations to increase cancer treatment effectiveness. Front. Immunol.8, 1804 (2017).
   PubMed Web of Science ®Google Scholar
• Nagata M , MutoS , HorieS. Molecular biomarkers in bladder cancer: novel potential indicators of prognosis and treatment outcomes. Dis. Markers2016, 8205836 (2016).
   PubMed Web of Science ®Google Scholar
• Gold DV , LewK , MaliniakR , HernandezM , CardilloT. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int. J. Cancer57(2), 204–210 (1994).
   PubMed Web of Science ®Google Scholar
• Gold DV , KaranjawalaZ , ModrakDE , GoldenbergDM , HrubanRH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin. Cancer Res.13(24), 7380–7387 (2007).
   PubMed Web of Science ®Google Scholar
• Gold DV , NewsomeG , LiuD , GoldenbergDM. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol. Cancer12(1), 143 (2013).
   PubMed Web of Science ®Google Scholar
• Cardillo TM , YingZ , GoldDV. Therapeutic advantage of 90yttrium-versus 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin. Cancer Res.7(10), 3186–3192 (2001).
   PubMed Web of Science ®Google Scholar
• Gold DV , CardilloT , VardiY , BlumenthalRJIJOC. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int. J. Cancer71(4), 660–667 (1997).
   PubMed Web of Science ®Google Scholar
• Gold DV , CardilloT , GoldenbergDM , SharkeyRM. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit. Rev. Oncol. Hematol.39(1–2), 147–154 (2001).
   PubMed Web of Science ®Google Scholar
• Gulec S , PenningtonK , BruetmanDet al. A Phase-I study of 90Y-hPAM4 (humanized anti-MUC1 monoclonal antibody) in patients with unresectable and metastatic pancreatic cancer. J. Nucl. Med.48(Suppl. 2), 393P–393P (2007).
   Google Scholar
• Fang Y , FullwoodMJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinform.14(1), 42–54 (2016).
   PubMed Web of Science ®Google Scholar
• Picozzi VJ , RamanathanRK , LoweryMAet al. 90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: a Phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur. J. Cancer51(14), 1857–1864 (2015).
   PubMed Web of Science ®Google Scholar
• Curry JM , ThompsonKJ , RaoSGet al. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J. Surg. Oncol.107(7), 713–722 (2013).
   PubMed Web of Science ®Google Scholar
• Vivero-Escoto JL , JeffordsLM , DréauD , Alvarez-BerriosM , MukherjeeP. Mucin1 antibody-conjugated dye-doped mesoporous silica nanoparticles for breast cancer detection in vivo. Presented at: Colloidal Nanoparticles for Biomedical Applications XII.San Francisco, CA, USA (2017).
   Google Scholar
• Moore LJ , RoyLD , ZhouRet al. Antibody-guided in vivo imaging for early detection of mammary gland tumors. Transl. Oncol.9(4), 295–305 (2016).
   PubMed Web of Science ®Google Scholar
• Bose M , MukherjeeP. A novel antibody blocks anti-apoptotic activity of MUC1 in pancreatic cancer cell lines. Cancer Res.79(Suppl. 13), 2052 (2019).
   Web of Science ®Google Scholar
• Ilovich O , KellyV , WuSet al. Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer. J. Med. Imaging Radiat. Oncol.50, S113 (2019).
   Google Scholar
• Ceriani RL , ChanCM , BarattaFS , OzzelloL , DerosaCM , HabifDV. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int. J. Cancer51(3), 343–354 (1992).
   PubMed Web of Science ®Google Scholar
• Mizrachi H , SalakoQA , FurmanskiP , GlennSD , DenardoGL. Radioimmunolocalization of metastatic breast carcinoma using Indium-ill-Methyl Benzyl DTPA BrE-3 monoclonal antibody: Phase I study. J. Nucl. Med.34(7), 1067–1074 (1993).
   PubMed Web of Science ®Google Scholar
• Denardo SJ , KramerEL , O'donnellRTet al. Radioimmunotherapy for breast cancer using indium-lll/yttrium-90 BrE-3: results of a phase I clinical trial. J. Nucl. Med.38(8), 1180–1185 (1997).
   PubMed Web of Science ®Google Scholar
• Denardo SJ . Radioimmunodetection and therapy of breast cancer. Presented at: Semin. Nucl. Med.35(2), 143–151 (2005).
   PubMed Web of Science ®Google Scholar
• Kramer EL , LiebesL , WasserheitCet al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin. Cancer. Res.4(7), 1679–1688 (1998).
   PubMed Web of Science ®Google Scholar
• Pietersz GA , WenjunL , KrauerK , BakerT , WreschnerD , MckenzieIF. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer Immunol. Immunother.44(6), 323–328 (1997).
   PubMed Web of Science ®Google Scholar
• Davies Q , PerkinsA , RoosJet al. An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. Br. J. Obstet. Gynaecol.106(1), 31–37 (1999).
   PubMedGoogle Scholar
• Gillespie A , BroadheadT , ChanSet al. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann. Oncol.11(6), 735–741 (2000).
   PubMed Web of Science ®Google Scholar
• Chan SY , GordonAN , ColemanREet al. A Phase II study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother.52(4), 243–248 (2003).
   PubMed Web of Science ®Google Scholar
• Price M , PughJ , HudeczFet al. C595–a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br. J. Cancer61(5), 681 (1990).
   PubMed Web of Science ®Google Scholar
• Song EY , QuCF , RizviSMet al. Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol. Ther.7(1), 76–80 (2008).
   PubMed Web of Science ®Google Scholar
• Hughes O , BishopM , PerkinsAet al. Targeting superficial bladder cancer by the intravesical administration of copper-67–labeled anti-MUC1 mucin monoclonal antibody C595. J. Clin. Oncol.18(2), 363–363 (2000).
   PubMed Web of Science ®Google Scholar
• Hughes O , PerkinsA , FrierMet al. Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. BJU Int.87(1), 39–46 (2001).
   PubMed Web of Science ®Google Scholar
• Dian D , JanniW , KuhnCet al. Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Oncol. Res. Treat.32(5), 238–244 (2009).
   Google Scholar
• Danielczyk A , StahnR , FaulstichDet al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol. Immunother.55(11), 1337–1347 (2006).
   PubMed Web of Science ®Google Scholar
• Fiedler W , DedossoS , CrestaSet al. A Phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Eur. J. Cancer63, 55–63 (2016).
   PubMed Web of Science ®Google Scholar
• Ledermann J , SehouliJ , ZurawskiBet al. LBA41A double-blind, placebo-controlled, randomized, Phase II study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. Ann. Oncol.28(Suppl. 5), 626 (2017).
   Google Scholar
• Garralda E , Van HoefM , OchsenreitherSet al. 1510TiP The GATTO study: a Phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. Ann. Oncol.29, 292–131 (2018).
   PubMedGoogle Scholar
• Qi W , SchultesBC , LiuD , KuzmaM , DeckerW , MadiyalakanR. Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybridoma Hybridomics20(5–6), 313–324 (2001).
   PubMedGoogle Scholar
• De Bono J , RhaSY , StephensonJet al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol.15(12), 1825–1833 (2004).
   PubMed Web of Science ®Google Scholar
• Mehla K , TremayneJ , GrunkemeyerJAet al. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors. Cancer Immunol. Immunother.67(3), 445–457 (2018).
   PubMed Web of Science ®Google Scholar
• Kearse KP , SmithNL , SemerDAet al. Monoclonal antibody DS6 detects a tumor-associated sialoglycotope expressed on human serous ovarian carcinomas. Int. J. Cancer88(6), 866–872 (2000).
   PubMed Web of Science ®Google Scholar
• Trombe M , CaronA , TellierAet al. Preclinical activity of an antibody drug conjugate targeting tumor specificmuc1 structural peptide-glycotope. Cancer Res.79(Suppl. 13), 235 (2019).
   Web of Science ®Google Scholar
• Gomez-Roca CA , BoniV , MorenoVet al. A Phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870). J. Clin. Oncol.34(Suppl. 15), 2511 (2016).
   Web of Science ®Google Scholar
• Calvete JA , NewellDR , WrightAF , RoseMS. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer. Cancer Res.54(17), 4684–4690 (1994).
   PubMed Web of Science ®Google Scholar
• Baeckström D , HanssonGC , NilssonO , JohanssonC , GendlerSJ , LindholmL. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J. Biol. Chem.266(32), 21537–21547 (1991).
   PubMed Web of Science ®Google Scholar
• Tolcher AW , OchoaL , HammondLAet al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol.21(2), 211–222 (2003).
   PubMed Web of Science ®Google Scholar
• Rodon J , GarrisonM , HammondLAet al. Cantuzumab mertansine in a three-times a week schedule: a Phase I and pharmacokinetic study. Cancer Chemother. Pharmacol.62(5), 911–919 (2008).
   PubMed Web of Science ®Google Scholar
• Mita M , RicartA , MitaAet al. A Phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors. J. Clin. Oncol.25(Suppl. 18), 3062–3062 (2007).
   Web of Science ®Google Scholar
• Goff L , PapadopoulosK , PoseyJet al. A Phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal (GE) junction cancer. J. Clin. Oncol.27(15S), e15625–e15625 (2009).
   Google Scholar
• Biassoni L , GranowskaM , CarrollMet al. 99m Tc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection. Br. J. Cancer77(1), 131 (1998).
   PubMed Web of Science ®Google Scholar
• You F , JiangL , ZhangBet al. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci. China Life Sci.59(4), 386–397 (2016).
   PubMed Web of Science ®Google Scholar
• Paknejad M , RasaeeM , TehraniFKet al. Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin. Hybridoma Hybridomics22(3), 153–158 (2003).
   PubMedGoogle Scholar
• Mohammadi M , RasaeeMJ , RajabibazlM , PaknejadM , ZareM , MohammadzadehS. Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques. Hybridoma26(4), 223–230 (2007).
   PubMedGoogle Scholar
• Salouti M , RajabiH , BabaeiMet al. 99mTc direct radiolabeling of PR81, a new anti-MUC1 monoclonal antibody for radioimmunoscintigraphy. Iran. J. Nucl. Med.13(1), 7–16 (2005).
   Google Scholar
• Nishimura S-I , HinouH , NumataY , OnodaJ , NaitoS , OhyabuN. Anti-MUC1 antibody. ( U.S. Patent No. 8,722,856) (2014).
   Google Scholar
• Pelat T , HustM , HaleM , LefrancM-P , DübelS , ThullierP. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol.9(1), 60 (2009).
   PubMedGoogle Scholar
• Thie H , ToleikisL , LiJet al. Rise and fall of an anti-MUC1 specific antibody. PLoS ONE6(1), e15921 (2011).
   PubMed Web of Science ®Google Scholar
• Yonezawa S , KitajimaS , HigashiMet al. A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach. Gastric Cancer15(4), 370–381 (2012).
   PubMed Web of Science ®Google Scholar
• Ismaili A , Jalali-JavaranM , RasaeeMJ , RahbarizadehF , Forouzandeh-MoghadamM , MemariHR. Production and characterization of anti-(mucin MUC1) single-domain antibody in tobacco (Nicotiana tabacum cultivar Xanthi). Biotechnol. Appl. Biochem.47(1), 11–19 (2007).
   PubMedGoogle Scholar
• Sadeqzadeh E , RahbarizadehF , AhmadvandD , RasaeeMJ , ParhamifarL , MoghimiSM. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J. Control. Release156(1), 85–91 (2011).
   PubMed Web of Science ®Google Scholar
• Pichinuk E , BenharI , JacobiOet al. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells. Cancer Res.72(13), 3324–3336 (2012).
   PubMed Web of Science ®Google Scholar
• Rubinstein DB , KarmelyM , ZivRet al. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 A/B junction antibodies that target malignant cells. Cancer Res.66(23), 11247–11253 (2006).
   PubMed Web of Science ®Google Scholar
• Panchamoorthy G , JinC , RainaDet al. Targeting the human MUC1-C oncoprotein with an antibody–drug conjugate. JCI Insight3(12), e99880 (2018).
   PubMed Web of Science ®Google Scholar
• Wu G , KimD , KimJNet al. A Mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed Mucin1 in breast cancer. Int. J. Mol. Sci.8(1), 78 (2018).
   Google Scholar
• Wu G , MaharjanS , KimDet al. A novel monoclonal antibody targets mucin1 and attenuates growth in pancreatic cancer model. Int. J. Mol. Sci.19(7), 2004 (2018).
   PubMed Web of Science ®Google Scholar
• Kim MJ , ChoiJR , TaeNet al. Novel antibodies targeting MUC1-C showed anti-metastasis and growth-inhibitory effects on human breast cancer cells. Int. J. Mol. Sci.21(9), 3258 (2020).
   PubMed Web of Science ®Google Scholar
• Naito S , TakahashiT , OnodaJet al. Generation of novel anti-MUC1 monoclonal antibodies with designed carbohydrate specificities using MUC1 glycopeptide library. ACS Omega2(11), 7493–7505 (2017).
   PubMed Web of Science ®Google Scholar
• Palitzsch B , GaidzikN , StergiouNet al. A synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer. Angew. Chem. Int.55(8), 2894–2898 (2016).
   PubMed Web of Science ®Google Scholar
• Stergiou N , NagelJ , PektorSet al. Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer. Int. J. Med. Sci.16(9), 1188 (2019).
   PubMed Web of Science ®Google Scholar
• Wakui H , TanakaY , OseTet al. A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes. Chem. Sci.11(19), 4999–5006 (2020).
   PubMed Web of Science ®Google Scholar
• Doi M , YokoyamaA , KondoKet al. Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping. Cancer Sci.97(5), 420–429 (2006).
   PubMed Web of Science ®Google Scholar
• Ohyabu N , HinouH , MatsushitaTet al. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. J. Am. Chem. Soc.131(47), 17102–17109 (2009).
   PubMed Web of Science ®Google Scholar
• Namba M , HattoriN , HamadaHet al. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1. Cancer Lett.442, 31–39 (2019).
   PubMed Web of Science ®Google Scholar
• Matsumura K , NikiI , TianHet al. Radioimmunoscintigraphy of pancreatic cancer in tumor-bearing athymic nude mice using 99m technetium-labeled anti-KL-6/MUC1 antibody. Radiat. Med.26(3), 133 (2008).
   PubMedGoogle Scholar
• Yamamoto M , BhavanandanV , NakamoriS , IrimuraT. A novel monoclonal antibody specific for sialylated MUC1 mucin. Jap. J. Cancer Res.87(5), 488–496 (1996).
   PubMedGoogle Scholar
• Suzuki H , ShodaJ , KawamotoTet al. Expression of MUC1 recognized by monoclonal antibody MY. 1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. Clin. Exp. Metastasis21(4), 321–329 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshimura Y , Denda-NagaiK , TakahashiYet al. Products of chemoenzymatic synthesis representing MUC1 tandem repeat unit with T-, ST-or STn-antigen revealed distinct specificities of anti-MUC1 antibodies. Sci. Rep.9(1), 1–12 (2019).
   PubMedGoogle Scholar
• Muguruma N , ItoS. Labeled anti-mucin antibody detectable by infrared-fluorescence endoscopy. Cancer Biomark.4(6), 321–328 (2008).
   PubMed Web of Science ®Google Scholar
• Ryuko K , ScholDJ , SnijdewintFGet al. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1. Tumor Biol.21(4), 197–210 (2000).
   PubMedGoogle Scholar
• Tarp MA , SørensenAL , MandelUet al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology17(2), 197–209 (2007).
   PubMed Web of Science ®Google Scholar
• Sørensen AL , ReisCA , TarpMAet al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology16(2), 96–107 (2006).
   PubMed Web of Science ®Google Scholar
• Posey AD Jr , SchwabRD , BoesteanuACet al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity44(6), 1444–1454 (2016).
   PubMed Web of Science ®Google Scholar
• King T , PoseyA. Co-expression of an engineered cell-surface sialidase by CART cells improves anti-cancer activity of NK cells in solid tumors. Cytotherapy21(5), S27 (2019).
   Web of Science ®Google Scholar
• Li Y , ZhouC , LiJet al. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. PLoS ONE13(1), e0191024 (2018).
   PubMed Web of Science ®Google Scholar
• Katayose Y , KudoT , SuzukiMet al. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res.56(18), 4205–4212 (1996).
   PubMed Web of Science ®Google Scholar
• Hinoda Y , NakagawaN , OheYet al. Recognition of the polypeptide core of mucin by monoclonal antibody MUSE11 against an adenocarcinoma-associated antigen. Jap. J. Cancer Res.81(12), 1206–1209 (1990).
   PubMedGoogle Scholar
• Takemura S-I , AsanoR , TsumotoKet al. Construction of a diabody (small recombinant bispecific antibody) using a refolding system. Protein Eng.13(8), 583–588 (2000).
   PubMedGoogle Scholar
• Takemura S-I , KudoT , AsanoRet al. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol. Immunother.51(1), 33–44 (2002).
   PubMed Web of Science ®Google Scholar
• Runcie K , BudmanDR , JohnV , SeetharamuNJMM. Bi-specific and tri-specific antibodies-the next big thing in solid tumor therapeutics. Mol. Med.24(1), 50 (2018).
   PubMedGoogle Scholar
• Goletz S , KehlerP , GellertJ , DanielczykA , JäkelA. Multispecific antibody constructs binding to muc1 and cd3. https://patents.google.com/patent/US20200131275A1/en (2020).
   Google Scholar
• Kodama H , SuzukiM , KatayoseYet al. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol. Lett.81(2), 99–106 (2002).
   PubMed Web of Science ®Google Scholar
• Schuhmacher J , KlivényiG , KaulSet al. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl. Med. Biol.28(7), 821–828 (2001).
   PubMed Web of Science ®Google Scholar
• Kufe DW . Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer9(12), 874–885 (2009).
   PubMed Web of Science ®Google Scholar
• Thie H , ToleikisL , LiJet al. Rise and fall of an anti-MUC1 specific antibody. PLoS ONE6(1), e15921 (2011).
   PubMed Web of Science ®Google Scholar
• Moreno M , BontkesHJ , ScheperRJ , KenemansP , VerheijenRH , Von Mensdorff-PouillyS. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett.257(1), 47–55 (2007).
   PubMed Web of Science ®Google Scholar
• Tang Y , CuiX , XiaoHet al. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer. Mol. Med. Rep.15(5), 2659–2664 (2017).
   PubMed Web of Science ®Google Scholar
• Treon SP , MaimonisP , BuaDet al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood96(9), 3147–3153 (2000).
   PubMed Web of Science ®Google Scholar
• Storr SJ , RoyleL , ChapmanCJet al. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology18(6), 456–462 (2008).
   PubMed Web of Science ®Google Scholar
• Pegram M , BorgesV , FuloriaJet al. Phase I pharmacokinetics (PK) of humanized anti-MUC-1 antibody R1550. J. Clin. Oncol.24(Suppl. 18), 2533–2533 (2006).
   Web of Science ®Google Scholar
• Zhou D , XuL , HuangW , TonnT. Epitopes of MUC1 tandem repeats in cancer as revealed by antibody crystallography: toward glycopeptide signature-guided therapy. Molecules23(6), 1326 (2018).
   PubMed Web of Science ®Google Scholar
• Singh R , BandyopadhyayD. MUC1: a target molecule for cancer therapy. Cancer Biol. Ther.6(4), 481–486 (2007).
   PubMed Web of Science ®Google Scholar
• Ledermann J , SehouliJ , ZurawskiBet al. LBA41A double-blind, placebo-controlled, randomized, Phase II study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. 28(Suppl. 5), (2017).
   Google Scholar
• Madsen CB , WandallHH , PedersenAE. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy. Immunopharmacol. Immunotoxicol.35(6), 649–652 (2013).
   PubMed Web of Science ®Google Scholar
• Zhao Q , PiyushT , ChenCet al. MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis. Cell Death Dis.5(10), e1438–e1438 (2014).
   PubMedGoogle Scholar
• Mcguckin MA , HurstTG , WardBG. Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma. Int. J. Cancer63(3), 412–418 (1995).
   PubMed Web of Science ®Google Scholar
• Walsh MD , LuckieSM , CummingsMC , AntalisTM , McguckinMA. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res. Treat.58(3), 253–264 (1999).
   Web of Science ®Google Scholar
• Reilly RM , SandhuJ , Alvarez-DiezTM , GallingerS , KirshJ , SternH. Problems of delivery of monoclonal antibodies. Clin. Pharmacokinet.28(2), 126–142 (1995).
   PubMed Web of Science ®Google Scholar